Physician profile
Guoping Zhou
NPI 1083634166
$8,512.75
in general payments reported to CMS, 2019-2025
49 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $228 · 2021: $1,694 · 2022: $838 · 2023: $1,019 · 2024: $1,851 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,324.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $983.64 | 2021-2025 | Relistor |
| Welch Allyn | $765.54 | 2021 | |
| Abbvie INC. | $748.12 | 2022-2025 | Qulipta, Ubrelvy |
| Corcept Therapeutics | $719.66 | 2024-2025 | Korlym |
| Neurocrine Biosciences, INC. | $672.32 | 2019-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $510.92 | 2021-2025 | |
| Scpharmaceuticals INC. | $481.74 | 2024-2025 | |
| Amgen INC. | $404.03 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $391.86 | 2021-2025 | Verquvo, Steglatro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $365.06 | 2020-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $316.75 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $288.39 | 2025 | Recorlev |
| Acorda Therapeutics, INC | $213.67 | 2019 | |
| Paratek Pharmaceuticals, INC. | $188.71 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.12 | 2023-2025 | Jardiance |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guoping Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.